Terms: = Ovarian cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Prognosis
3 results:
1. Clinical value of survivin and its underlying mechanism in ovarian cancer: A bioinformatics study based on GEO and TCGA data mining.
Li XJ; Pang JS; Li YM; Ahmed FA; He RQ; Ma J; Ma FC; Chen G
Pathol Res Pract; 2018 Mar; 214(3):385-401. PubMed ID: 29499854
[TBL] [Abstract] [Full Text] [Related]
2. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
[TBL] [Abstract] [Full Text] [Related]
3. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National cancer Institute of Canada Clinical Trials Group Report.
Klaassen D; Starreveld A; Shelly W; Miller A; Boyes D; Gerulath A; Levitt M
Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1801-4. PubMed ID: 4044343
[TBL] [Abstract] [Full Text] [Related]
